HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Lumos Pharma (NASDAQ:LUMO) and maintained a $28 price target.
March 20, 2024 | 4:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Lumos Pharma with a $28 price target.
The reiteration of a Buy rating and maintenance of a $28 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence in investors and potentially drive Lumos Pharma's stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100